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ABSTRACT
In biology and biomedicine, relating phenotypic out-
comes with genetic variation and environmental fac-
tors remains a challenge: patient phenotypes may
not match known diseases, candidate variants may
be in genes that haven’t been characterized, research
organisms may not recapitulate human or veterinary
diseases, environmental factors affecting disease
outcomes are unknown or undocumented, and many
resources must be queried to find potentially signif-
icant phenotypic associations. The Monarch Initia-
tive (https://monarchinitiative.org) integrates infor-
mation on genes, variants, genotypes, phenotypes
and diseases in a variety of species, and allows
powerful ontology-based search. We develop many
widely adopted ontologies that together enable so-
phisticated computational analysis, mechanistic dis-
covery and diagnostics of Mendelian diseases. Our
algorithms and tools are widely used to identify an-
imal models of human disease through phenotypic
similarity, for differential diagnostics and to facilitate
translational research. Launched in 2015, Monarch
has grown with regards to data (new organisms,
more sources, better modeling); new API and stan-
dards; ontologies (new Mondo unified disease ontol-
ogy, improvements to ontologies such as HPO and
uPheno); user interface (a redesigned website); and
community development. Monarch data, algorithms
and tools are being used and extended by resources
such as GA4GH and NCATS Translator, among oth-
ers, to aid mechanistic discovery and diagnostics.
INTRODUCTION
The quest to elucidate the genetic basis of disease is ham-
pered by the fragmented landscape of clinical and organ-
ismal data. The Monarch Initiative is an open-source re-
source that has amassed a large collection of genotype–
phenotype data: over two million phenotypic associations
from dozens of sources covering over 100 species. Monarch
provides a bridge between basic and clinical research, de-
veloping tools to connect data from multiple sources us-
ing ontologies and semantic data integration. Over the past
three years, we have introduced and extended numerous in-
tegrated ontologies for disease, phenotype, genotype and
anatomy, to enable deep semantic integration and cross-
species querying. Monarch’s data resources, APIs and anal-
ysis tools are used both internally and by external groups to
bring the power of research organismal data to the clinical
domain. Monarch has pioneered the use of research organ-
ism data for rare disease diagnosis, and a number of our
resources have become global standards.
PRODUCTS OF THE MONARCH INITIATIVE
Ontologies
Monarch develops methods and tools that not only sup-
port precision medicine and disease modeling, but also sup-
port mechanistic exploration of the relationships between
genotype, environment and phenotype across the tree of
life. We do this by using ontologies to leverage semantic
relationships between biological concepts. Members of the
Monarch Initiative and our collaborators have developed
key ontological resources such as the Human Phenotype
Ontology (HPO); have employed innovative techniques to
harmonize phenotype ontologies in the Unified Phenotype
Ontology (uPheno); have similarly harmonized disease ter-
minologies in the creation of Mondo; and continue to de-
velop these and other resources that work together to build
toward an interoperable semantic landscape. Below, we de-
scribe our latest work on ontologies.
The Human Phenotype Ontology (HPO). For proper se-
mantic representation of clinical abnormalities and its as-
sociations to diseases we developed the HPO. HPO (https:
//hpo.jax.org), a flagship of Monarch, is a standardized vo-
cabulary of phenotypic abnormalities associated with over
7000 diseases (1). HPO is the de facto standard terminol-
ogy for clinical ‘deep phenotyping’ in humans, providing
detailed descriptions of clinical abnormalities and com-
putable disease definitions. This ontology enables non-exact
matching of sets of phenotypic features (phenotype profiles)
against known diseases, other patients and research organ-
isms. The primary labels in the HPO employ medical ter-
minology used by clinicians and researchers. To make the
HPO more accessible to patients and non-medical experts,
we added layperson synonyms, where appropriate (2). The
HPO currently contains 4887 terms with at least one lay
synonym, and these are available via the HPO website or
in the OWL file with the ‘layperson term’ subset tag.
Algorithms based on HPO have been implemented in
many diagnostic and variant prioritization tools and are
used by the UK’s 100 000Genomes Project (3), the USNIH
Undiagnosed Diseases Program (4) and Network (5), and
thousands of other clinics, labs, tools, and databases world-
wide. We have developed strong ties with clinical adopters
to continue improving specific areas of the ontology and ex-
tend standardized disease descriptions. Initially developed
for rare disease phenotyping, HPO also captures many phe-
notypes for common diseases and can be used as a general
resource for patient phenotyping. We continue to explore
patient phenotyping from other sources of electronic health
records (EHRs) and to promote the adoption of HPO in
health care systems (6).
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Figure 1. uPheno template-driven ontology development and harmoniza-
tion. uPheno templates are used to define phenotypes according to agreed
upon design patterns. (A). Computable definitions specified using uPheno
templates are used to automate classification of uPheno and parts of the
Zebrafish Phenotype Ontology (ZP (13); dashed lines). (B). Computable
definitions also drive automated classification of HPO and ZP classes un-
der uPheno classes. For example, enlarged heart in ZP (defined using the
zebrafish anatomy heart term) and enlarged heart in HPO are both clas-
sified under uPheno enlarged heart (defined using Uberon heart). Algo-
rithms can use this classification under uPheno to predict that human or-
thologs of zebrafish genes annotated to enlarged heart may cause enlarged
heart in humans.
The Unified Phenotype Ontology (uPheno). Different on-
tologies are used to represent the phenotypes in humans
and in each of the major model organism groups. For ex-
ample, the Mammalian Phenotype (MP) ontology (7) is
used by the Mouse Genome Informatics resource (MGI)
(8) to annotate mouse phenotypes, HPO by Monarch for
human phenotypes and the Drosophila Phenotype Ontol-
ogy (9) by FlyBase for Drosophila Phenotypes. The Ze-
brafish Information Network (ZFIN) (10) uses a different
approach, describing zebrafish phenotypes with terms from
reference ontologies such as the Phenotype And Trait On-
tology (PATO; http://www.obofoundry.org/ontology/pato)
and the Gene Ontology (GO) (11). To enable cross-species
querying of phenotypes we have developed an approach
for integrating these ontologies based on logical definitions
(12), called the Entity-Quality (EQ) approach. In 2013 we
implemented this approach in the Unified Phenotype On-
tology (uPheno) that integrates organism-specific pheno-
type ontologies using ‘bridging axioms’ that connect terms
from different ontologies using equivalence or subsumption
axioms (13).
The Monarch Initiative uses uPheno (http://obofoundry.
org/ontology/upheno) to find candidate genes and poten-
tial animal models for human diseases. For this to work
well, similar terms both within and between phenotype
ontologies need to be described in a logically consistent
manner (14). However, while the EQ approach was widely
adopted by important model organism communities such
ZFIN (10), MGI (8), WormBase (15) and FlyBase (16),
the logical definitions themselves were developed in rel-
ative isolation, which often caused them to be semanti-
cally incompatible. In 2018, we launched a community-
wide effort to reconcile and align phenotype ontologies (17)
which defined templates based on the Dead Simple On-
tology Design Pattern (DOSDP) (18) framework (Figure
1) for the consistent and interoperable representation of
phenotypes (for more details on the Reconciliation Effort
see section ‘Community Engagement’). Based on these pat-
terns, we developed a novel framework (https://github.com/
obophenotype/upheno-dev) for the automated construc-
tion of uPheno (https://f1000research.com/posters/8-403).
We are currently working closely with members from 14
phenotype ontologies and databases to expand the cov-
erage of species-specific phenotypes in uPheno with or-
ganisms including C.elegans, Xenopus, Dictyostelium dis-
coideum, Schizosaccharomyces pombe and more. This work
advances a core mission of the Monarch Initiative: to lever-
age the wealth of phenotypic knowledge generated by the
study of multiple species to understand the genetic nature
of human disease.
Mondo: The unified disease ontology. Mondo (http://
obofoundry.org/ontology/mondo) is an ontology of dis-
eases and disorders with over 23 000 terms describing a va-
riety of diseases spanning Mendelian, rare, common, com-
plex, infectious and cancer. We created Mondo by inte-
grating available knowledge sources, defining which terms
are truly equivalent across different resources. The result
thereby enables the integration of associated information,
such as treatments, genetics and phenotypes for diagnostics
and mechanism discovery. There are many disease termi-
nologies (19), with terms that typically cross-reference each
other in ambiguous and conflicting ways. Mondo combines
disease information from sources such as OMIM (20), Or-
phanet (21) andNCIt (National Cancer Institute Thesaurus
(22)), in order to leverage the strengths of each resource,
including the neoplastic disease classification of NCIt, the
rare disease coverage of Orphanet, the Mendelian cover-
age of OMIM and the common disease coverage of other
resources. The Mondo build process uses novel, scalable
computational methods to find, untangle and resolve con-
flicts occurring when disease nomenclatures are merged us-
ing cross-references. As a result, Mondo is a logically coher-
ent, merged disease ontology, and it constitutes a scalable
solution to the challenge of integrating multiple, partially
overlapping and partially conflicting disease terminologies.
TheMondo ontology is used in a growing number of bioin-
formatics resources, including ClinGen (23), the Genetic
and Rare Diseases Information Center (GARD, https://
rarediseases.info.nih.gov), the European Bioinformatics In-
stitute (EMBL-EBI) as a component of the Experimental
Factor Ontology (EFO) (24) and the Kids First Data Re-
source Portal (https://kidsfirstdrc.org). Initially constructed
using semi-automatic methods (25), Mondo is now exten-
sively manually curated. A new release for Mondo is avail-
able monthly.
SEPIO. Monarch developed the SEPIO ontology-based
data modeling framework for representing evidence and
provenance behind scientific assertions (http://obofoundry.
org/ontology/sepio). SEPIO stands for Scientific Evidence
and Provenance Information Ontology. Initially devel-
oped to support harmonized representation of the di-
verse evidence and provenance information across knowl-
edge sources integrated by Monarch, SEPIO has since
been adopted and expanded by external efforts. For ex-
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Figure 2. Decomposition of a Zebrafish Genotype. The left panel shows
classes in the core genotype partonomy. The center panel shows an ex-
ample instance of each class from the zebrafish genotype (see also https:
//zfin.org/ZDB-GENO-161227-1). The right panel shows a graphical de-
piction of the portion of the genome specified at each level (where the
top panel shows a complete genome composed of two sets of homologous
chromosomes).
ample, the ClinGen consortium is defining SEPIO-based
data models for all five of its curation pipelines, including
a Variant Pathogenicity Interpretation data model aligned
with the 2015 ACMG Guidelines (https://dataexchange.
clinicalgenome.org/interpretation). Several other projects
are in the process of defining SEPIO-based data models, in-
cluding the Variant Interpretation in Cancer Consortium
(VICC, https://cancervariants.org), and the GA4GH Ge-
nomic Knowledge Standards working group.
GENO. The Genotype Ontology, GENO (http:
//obofoundry.org/ontology/geno), is an ontology that
represents the various components of genotypes, their rela-
tionships, and their characteristics. Figure 2 shows classes
in the core GENO partonomy (e.g. transitive parts), which
decompose a complete genotype into smaller components
that reflect the levels at which phenotype annotations
are made in different genotype–phenotype resources. For
example, ZFIN and MGI annotate full zebrafish and
mouse genotypes, respectively, while WormBase annotates
gene alleles, and ClinVar (26) annotates individual human
sequence alterations (e.g. a single nucleotide variation).
The logic encoded in the GENO ontology allows inference
of phenotype associations in a way that enables integrated
analysis of data across knowledge sources and species. For
example, a phenotype annotation made on the zebrafish
genotype'fgf3t24149/+(AB)' can be propagated down the
partonomy to the 'fgf3t24149' gene allele, allowing direct
comparison with data from sources such as WormBase that
annotate phenotypes directly on gene alleles.
We have recently evolved GENO to accommodate new
use cases from various community partners. For exam-
ple, we have coordinated with the ClinGen Data Exchange
Working Group (http://dataexchange.clinicalgenome.org)
to add terms describing copy number variation, allelic
phase, allele origin, and allelic state. We are also work-
ing with the Alliance of Genome Resources (https://
www.alliancegenome.org) to align core GENO terms with
genotype-related concepts used in themodel organism com-
munity. These efforts will facilitate use of GENO to inte-
grate data across a broader set of resources.
The integrated Monarch ontology. Beyond the ontolo-
gies developed by the Monarch Initiative, the Monarch
platform brings together more than 30 ontologies includ-
ing GO, the Cell Ontology (CL) (27), Uberon (28) and
a number of organism-specific anatomy ontologies, such
as FBbt (Drosophila) (https://wiki.flybase.org/mediawiki/
images/a/a1/ISB2019 DAO.pdf) and ZFA (zebrafish) (29).
To leverage these diverse ontologies in our knowledge graph
and in the Monarch app, we have developed the Inte-
grated Monarch Ontology (https://github.com/monarch-
initiative/monarch-ontology). One of the key goals of the
MonarchOntology is to ensure interoperability between the
integrated source ontologies which often depend on incom-
patible versions of other ontologies. To that end, we are cur-
rently developing amodular strategy based on theOntology
Development Kit (ODK, https://github.com/INCATools/
ontology-development-kit). This strategy involves the inte-
gration and community wide deployment of so-called ‘base’
modules––subsets of the ontologies that contain only the
native axioms (axioms actually belonging to the ontology)
and exclude axioms from their respective ontology depen-
dencies. This ensures that only the latest versions of all on-
tologies make it into the knowledge graph and stale and
possibly incompatible dependencies on old versions are ex-
cluded. The Monarch Ontology forms the upper ontolog-
ical layer of our knowledge and data graph, which will be
described in the following sections.
THE MONARCH ARCHITECTURE AND API
Monarch architecture
As previously reported, we developed an ETL (Extract,
Transform, Load) pipeline called Dipper (https://github.
com/monarch-initiative/dipper), which ingests a wide range
of data sources, including genes, mechanisms and con-
text, as well as phenotypic and disease data from disparate
sources including research organism and human databases.
After ingestion, these data sources are regularized to con-
form to common association patterns according to the Bi-
oLink Model (https://biolink.github.io/biolink-model), are
augmented with terms from many ontologies, and are pub-
lished individually in the Resource Description Frame-
work (RDF) format at https://archive.monarchinitiative.
org/latest. These intermediate RDF data files, as well as all
referenced ontologies, are unified with SciGraph (https://
github.com/SciGraph/SciGraph), an application that wraps
a Neo4j graph database and manages the transformation of
ontologies and data described using ontologies into a com-
bined graph which is henceforth referred to as theMonarch
knowledge graph. This graph database serves as the primary
data store for Monarch and its applications. We query and
cache results from this graph database, indexing them with
an ontology-enhanced Solr instance called GOlr, to provide
quick access via ourMonarch API, an OpenAPI-compliant
data access layer (Figure 3).
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Figure 3. A workflow diagram of the Monarch architecture. Since our last report, we have developed the Monarch API (highlighted) for access-
ing associations between entities, performing computations on phenotype profiles, executing graph traversal queries, and performing text annotation
(https://api.monarchinitiative.org/api).
Data integration
We regularly update our database with the latest gene-
to-phenotype data from research organism databases (e.g.
MGD (8), ZFIN (10), WormBase (15), FlyBase (16), IMPC
(30)), human variants and gene-to-disease data (from
OMIM, ClinVar, Orphanet, GWASCatalog (31)) and other
organismal gene-to-phenotype resources (OMIA (32), An-
imal QTLdb (33)). As well, we ingest other genomic
data types, such as GO annotations, gene expression in
specific tissues (BgeeDB (34)), protein-to-protein interac-
tion (BioGRID (35)), pathway data (KEGG (36), Re-
actome (37)), chemical-disease associations (CTD (38)),
cell line genotypes-to-disease data (Coriell; https://www.
coriell.org), data from the Mouse Phenome Database
(39) and from the Mutant Mouse Resource and Re-
search Centers (MMRRC; https://www.mmrrc.org/, Office
of the Director grant number OD010921). We recently also
added data from the Rat Genome Database (RGD (40)),
the Saccharomyces Genome Database (SGD (41)) and
data from protein-to-protein interaction networks from
STRING (42). The latest release of theMonarch knowledge
graph (September 2019, https://archive.monarchinitiative.
org/latest) contains over 32.9 million nodes and 160 mil-
lion edges. In comparison to our previous report, we have
134 244 additional gene-to-phenotype associations. Nearly
half (68 640) of the new associations were the result of
adding SGDandRGDas new sources of data forMonarch,
while 65 604 were added from new data available for mouse,
zebrafish, nematode and human combined. Our database
now has 26 433 models of disease, a 44% increase since
our 2017 report in NAR (43). There are 2 982 400 high-
quality protein-protein interactions from STRING from 6
species, and 931 518 from BioGRID. Figure 4 summarizes
the sources, their data types, the ontologies used for integra-
tion and their delivery within Monarch’s knowledge graph.
Gene-to-disease and variant-to-disease data
In order to obtain a fine-grained resolution for genotype–
phenotype relationships in humans, Monarch ingests
variant-level data and gene-to-disease associations from
OMIM, Orphanet, ClinVar and GWAS Catalog. Each
source defines specific relationships between genes, variants
and diseases depending on different forms of supporting
evidence and other factors. Taken together, these sources
contain information about 13 different relationships, some
directly comparable and some not. Monarch uses these 13
relationships to link genes and variants to diseases, a sub-
set of which is reserved for causal associations between a
variation and a disorder, while others are utilized for non-
causal associations, such as susceptibility to complex dis-
eases, genome-wide association studies and variants that are
likely pathogenic for a condition. The two levels of associa-
tions are shown separately in the results tables on our web-
site, and can be queried separately using our API. Our latest
data release shows that 3799 protein coding genes are iden-
tified as being the main cause for one or more disorders, as
opposed to gene variants that contribute to disease suscep-
tibility.
Monarch application programming interface (API)
The Monarch API is a data access layer that sits on top
of Monarch’s knowledge graph and provides a standard
way to access information about entities and association be-
tween entities, perform ontology navigation, run semantic
similarity queries, perform annotation sufficiency scoring
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Figure 4. Monarch’s data sources. The leftmost set of columns shows the types of data that the integrated data sources serve to Monarch. Note that
these sources offer many additional data types that have not yet been integrated into Monarch. Each data source is annotated to specific ontologies and
standards, which are, in turn, harmonized using the ontologies indicated in the rightmost panel. Those are used to create an integrated knowledge graph
which drives the views and analytics on the Monarch website.
and annotate text with entities via named-entity recogni-
tion. Our API has a Swagger-generated documentation in-
terface (https://api.monarchinitiative.org/api/swagger.json)
that details all routes available for querying the Monarch
database, including required and optional input parame-
ters, JSON schema for the response, and working examples
to guide users as they explore each API endpoint. Entity
search supports labels, synonyms (e.g. layperson) and defi-
nitions. Search has been updated to include genotypes, vari-
ants and anatomical entities. All Monarch user interface
components are driven by this API (i.e. search, data tables
and text annotation). This unified data access layer enables
researchers and physicians to explore the Monarch data
on our website, and allow us to: (i) run phenotypic com-
parative analysis making use of semantic similarity soft-
ware; (ii) annotate text; and (iii) browse data using facets–
for example, disease or phenotype categories such as cardio-
vascular abnormalities (e.g. https://monarchinitiative.org/
phenotype/HP:0001626).
In order to simplify programmatic access to Monarch’s
resourceswe developedOntobio, a librarywritten in Python
and designed for work with ontologies and ontology associ-
ations. It supports a wide range of functionalities such as (i)
parsing and using ontologies; (ii) an object model for work-
ing with ontologies and their metadata elements; (iii) an
API for performing graph operations traversing through an
ontology; (iv) ways to access associations from Monarch’s
knowledge graph; (v) ways to access functional annotations
from the Gene Ontology; (vi) tools for performing enrich-
ment analyses with virtually any ontology and associations
for that ontology; and (vii) a command-line interface. Onto-
bio is freely available at https://github.com/biolink/ontobio.
As part of this library, we also provide examples of how to
use Ontobio for performing the aforementioned function-
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alities. Our API makes use of the Ontobio library for com-
municating withMonarch resources, enabling theMonarch
API to remain a lightweight data access layer.
THE NEW MONARCH USER INTERFACE
Monarch will soon be releasing a new, redesigned web
interface for Monarch users. The new website presents
users with a simplified format for accessing and explor-
ing our data. With the semantic tools available from the
Monarch Initiative, researchers, clinicians and the general
public can gather, collate and unify disease information
across human, research organisms and veterinary species
in a single platform. A beta version of the updated user
interface (UI) is available at https://beta.monarchinitiative.
org. The new UI is a single page application, written in
VueJS, that relies on various backend services, primar-
ily our new API (described above), to retrieve and dis-
play the data. The Monarch database integrates infor-
mation from 31 phenotype-related resources (https://beta.
monarchinitiative.org/about/data-sources), allowing users
to establish connections among biological entities of inter-
est, such as genes, genotypes, gene variants (including SNPs,
SNVs, QTLs, CNVs), models (including cell lines, animal
strains, species, breeds, as well as targeted mutants), path-
ways, orthologs, phenotypes and publications. From the
new home page, users will be able to exploreMonarch using
names or identifiers for phenotypes, diseases, genes, publi-
cations, variants or models of human disease. All of the in-
formation in the Monarch resource is organized using on-
tologies, rather than free text in isolation. This means that
features of the ontology can be used to assist users in search,
for example, finding a disease of interest using a synonym,
or using the hierarchical organization of a phenotype on-
tology to group annotations.
The main page for each phenotype, gene, or disease, the
‘Overview’ tab, offers a summary of all available informa-
tion in the integrated knowledge graph of the Monarch
database, and includes intuitive tools to enable users to nav-
igate through the available data (Figure 5). In addition to
finding associated terms from a variety of ontologies (for ex-
ample, anatomy, function, pathwaymembership, orthologs,
phenotypes) the updated user interface facilitates finding
publications in support of all associations displayed for
each term. Updated pages documenting the Patient Pheno-
type Curation Guidelines and the Monarch Phenotype On-
tologies Project are also available from the website, as well
as details about Exomiser, a Monarch tool used for priori-
tization of variants and candidate genes from whole exome
and whole genome sequencing efforts (described below).
Monarch Annotator
The new site, in addition to offering a range of options
to query the Monarch database through searches, includes
an updated version of our text annotation tool, which al-
lows users to automatically mark up phenotypes, diseases,
anatomical terms, genes and other entities found in text
from publications via a UI (Figure 6), or using web services.
This functionality was used to mine HPO (1) terms from
published case reports in biocuration applications such
as PhenoteFX (https://phenotefx.readthedocs.io/en/latest),
which helps curators revise or create phenotype annotation
records for rare disease and HpoCaseAnnotator, which is
used to biocurate pathogenic variants published in scientific
literature (https://hpocaseannotator.readthedocs.io).
COMMUNITY ENGAGEMENT
Monarch’s overarching goal is to galvanize translational re-
search by developing tools, data services and analysis ap-
proaches that help scientists analyze their results in the
context of genotype, phenotype and related data from a
range of sources. Progress toward this goal is a virtuous
loop: by building resources that benefit the community, we
also incentivize others to make their tools, ontologies and
data more interoperable, thereby making it even easier for a
wide range of researchers to leverage Monarch’s offerings.
Monarch is also collaborating closely with partners such as
GA4GH to develop shared standards and resources.
The ‘Great phenotype ontology reconciliation effort’
To catalyze phenotype ontology reconciliation, we ran
two workshops (Phenotype Ontologies: Traversing All
The Organisms, or ‘POTATO’). The first installment,
which took place at the International Conference on
Biological Ontologies (ICBO) in 2018, gathered more
than 40 ontology curators, developers and biomedical
experts to learn about our tools for pattern-based de-
velopment and to discuss discrepancies between logical
definitions across various phenotype ontologies. As a result
of the meeting, representatives of 14 phenotype ontolo-
gies and databases covering all major model organisms
joined a common Phenotype Ontology Reconciliation
Effort (https://github.com/obophenotype/upheno/wiki/
Phenotype-Ontologies-Reconciliation-Effort) focused
on aligning their respective ontologies by developing
and using common sets of design patterns to generate
logical definitions (17). The second POTATO work-
shop (44) was co-located with Biocuration 2019. It
focused on developing strategies to deal with the limi-
tations of the Phenotype And Trait Ontology (PATO,
http://www.obofoundry.org/ontology/pato), an essen-
tial driver of inference in phenotype ontologies. Key
accomplishments include the establishment of patterns
and workflows for ontological alignment across many
organisms; review and implementation of over 100
common design patterns across them, and the elim-
ination of many logical and lexical mistakes (https:
//douroucouli.wordpress.com/2018/08/06/new-version-of-
ontology-development-kit-now-with-docker-support/).
Most major phenotype ontologies are now using the Ontol-
ogy Development Kit (ODK, described in the ‘Ontologies’
section), which will assist with this standardization and
quality control according to OBOFoundry principles (http:
//www.obofoundry.org/principles/fp-000-summary.html).
The template-based generation of phenotype terms now
allows de-novo generation of born-interoperable, species-
specific phenotype ontologies from uPheno templates,
reducing the need for manual and error-prone curation
of class hierarchies. Examples of ontologies created de
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Figure 5. The NewMonarch User Interface. A beta version of the new website is available at https://beta.monarchinitiative.org. Entering information on
the ‘Search’ bar, users can navigate directly to terms suggested via autocomplete, or explore more results through the results tables. In this example, a user
enters only part of the name of a disease, ‘Pierpont syndrome’ (A). Selecting the term from the auto-complete menu, the user arrives at an overview page,
which offers a summary of all available information in the integrated knowledge graph of the Monarch database (B). Users can explore all available data
using a menu of options shown on a panel on the left (B-1), while the information is updated on the main panel on the right (B-2). In this example, the user
learns that Pierpont syndrome, a rare subcutaneous tissue disorder, is characterized by phenotypes that include ‘prominent subcalcaneal fat pad’ (a term
in HPO, with identifier HP:0032276), ‘deep plantar creases’ (HP:0001869) and ‘muscular hypotonia’ (HP:0001252), among many others (C). Information
integrated from the OMIMandOrphanet databases, as well as a number of publications, also support the association of amutation in one gene, TBL1XR1,
as the cause of Pierpont syndrome (D).
novo by this approach include the Xenopus Phenotype
Ontology (45) and the Planarian Phenotype Ontology
(http://www.obofoundry.org/ontology/planp.html).
Exomiser
Although whole-exome and genome sequencing have revo-
lutionized rare disease diagnostics, many cases of rare dis-
eases remain unsolved, in part because of the difficulty of
prioritizing the hundreds of candidate variants that may re-
main after removing those identified as common or non-
pathogenic. Exomiser (46) is an automated approach de-
veloped by the Monarch Initiative to address this problem;
it takes patient sequencing data and coded patient pheno-
types and analyzes both, informed by a large corpus of
gene-to-phenotype associations from humans and model
organisms. Exomiser is being used to expedite phenotype-
based variant prioritization and improve diagnosis rates in
national-level programs such as the rare disease compo-
nent of the UK 100 000 Genomes Project (https://www.
genomicsengland.co.uk), the NIH Undiagnosed Diseases
Program (4) and the European Solve-RD project (http://
solve-rd.eu), individual hospitals (47) and labs and com-
panies (congenica.com/products-and-services). It has also
been used for phenotype profile matching between patients
in the Matchbox tool (48) as part of the MatchMaker Ex-
change (MME) project (https://www.matchmakerexchange.
org/) and for automated panel assignment in the Genomics
England PanelAssigner tool.
Partnerships within the Global Alliance for Genomics and
Health, GA4GH
As an official Driver Project for GA4GH (https://www.
ga4gh.org), the Monarch Initiative provides requirements
and implementation testbeds, as well as personnel who
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Figure 6. Text annotation widget on the new Monarch website. Users can supply free text and retrieve the resulting marked up text with links to terms in
various ontologies. In this example, a user has entered text from a publication entitled ‘A specific mutation in TBL1XR1 causes Pierpont syndrome’ (51).
The Text Annotator tool (in beta version) has highlighted terms identified in various ontologies, and hovering over each highlighted term offers details
about the marked up annotations, in this case, ‘abnormal fat distribution.’
play active leadership roles in both the Clinical and Phe-
notypic Data Capture and Exchange (CP) and the Genomic
Knowledge Standards (GKS)Work Streams. TheGKSwork
has leveraged several Monarch resources in its emerging
standards, including the HPO, Mondo, the genotype on-
tology GENO and the ontology for evidence and prove-
nance information in science, SEPIO (see ‘Ontologies’ sec-
tion above). Because Monarch has been focused on the
use of phenotype ontologies and terminologies in clini-
cal and research settings, we have been significant con-
tributors to the new information model for the exchange
of clinical and genomic information, Phenopackets (https:
//github.com/phenopackets/phenopacket-schema). In part-
nership with HL7 (http://www.hl7.org/) and GA4GH, our
workstream is developing a FHIR (http://hl7.org/fhir/) im-
plementation guide for the Phenopackets schema, with the
high-level goal of increasing the availability of high-quality
standardized phenotypic information for genomic research
and genomic medicine across the translational divide.
NCATS Translator
The NCATS Biomedical Data Translator program (https:
//transltr.io) is building a structured data and machine rea-
soning ecosystem to address a wide range of questions
about human disease posed by researchers, clinicians and
patients. The three pillars of the Translator program are
(i) data in the form of knowledge graphs, (ii) reusable soft-
ware modules to perform computational tasks and analysis,
and (iii) reasoning systems that can use data relationships
and logic to provide possible answers to questions. The
Monarch Initiative provides key resources to the Translator
project by enabling programmatic queries via the Monarch
API and by providing pre-reasoned RDF for ingest into
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others’ knowledge graphs. The queries retrieve specific cu-
rated and structured data on phenotypes, functional anno-
tations and disease variants, as well as corresponding data
inmodel organisms including gene orthologs. TheMonarch
data serve as the foundation for core Translator computa-
tional modules for phenotype comparison and functional
similarity, as well as cross-species analytics. These modules
have been used in ongoing validations of Translator perfor-
mance including in a number of data-driven vignettes about
chosen exemplar diseases, resulting in the first public out-
puts from the Translator program.
DISCUSSION
TheMonarch Initiative works closely with experts from rel-
evant scientific data providers to ensure that the knowledge
graph is useful and the data are correctly represented. This
requires significant outreach with several communities of
users and data providers, which takes place in the context
of face-to-face workshops. Communities engaged in this
way include clinicians, curators, toxicologists, exposure sci-
entists, developmental biologists, comparative genomicists,
clinical researchers, rare disease researchers and epidemiol-
ogists. These workshops provided the opportunity for ex-
perts to communicate across domains, develop use cases
and provide feedback on data models. In addition to im-
proving the data model and the ontologies, these collabo-
rative workshops have inspired new collaborations and in-
creased general knowledge about bio-ontologies.
The Monarch Initiative has brought together 31 data re-
sources and made a real difference in the lives of patients
(49). Monarch has been an important part of projects like
GA4GH and the NCATS Translator. Future work will in-
clude development of HCLS-Compliant metadata, incor-
poration of additional datasets, further development of on-
tologies and extension of the data model to include environ-
mental exposures. While the Monarch Initiative will con-
tinue to focus on human disease, data acquisition andmodel
development, it will expand its scope toward a higher diver-
sity of species and domain expert contributions.
DATA AVAILABILITY
The Monarch platform is comprised of multiple compo-
nents: user interface, data, ontologies, software tools and
algorithms. The underlying data are derived from multiple
external sources, the use and secondary use of which is gov-
erned by the corresponding original license for each source;
as we have described in detail, this is not without complex
implications (50). It is therefore not possible to provide ev-
erything under a unified license. Our integrated data cor-
pus is available for bulk download as RDF formatted files,
with subsets of this data as tab-separated value files (https:
//archive.monarchinitiative.org/latest). Our Neo4j database
and Solr index are also publicly available in this archive. Our
API provides programmatic access to associations of indi-
vidual entities. General information about entities, such as
definitions, synonyms and cross references, is also available
at https://api.monarchinitiative.org/api. A glossary of terms
and abbreviations used in this manuscript can be found at
https://beta.monarchinitiative.org/glossary.
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